AZD1152 in Patients With Advanced Solid Malignancies-Study 3

A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 7-Day Intravenous Infusion in Patients With Advanced Solid Malignancies

The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 7-day infusion every week and every 2 weeks in patients with advanced solid malignancies.

Inclusion Criteria:

• Histological or cytological confirmation of a solid, malignant tumour

Exclusion Criteria:

• Participation in an investigational drug study within 21 days prior to entry or who have not recovered from the effects of an investigational study drug
• Treatment with radiotherapy/chemotherapy with 4 weeks of first dose
• Recent major surgery within 4 weeks prior to entry to the study